Method of treating cancer preferably characterized by expression of a fusion protein comprising a member of the e-twenty-six family by administering an agent that inhibits the synthesis and/or activity of cortisol
AssigneeYeda Research and Development Co. Ltd.
InventorsYosef YARDEN, Swati SRIVASTAVA
Life of this patent
Estimating the term…
Abstract
A method of treating a cancer selected from the group consisting of a myeloid malignancy, a lymphoid malignancy and Ewing's sarcoma is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol.
Claims18
A method of treating a cancer selected from the group consisting of a myeloid malignancy, a lymphoid malignancy and Ewing's sarcoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol, thereby treating the cancer.
A method of treating a subject having a cancer characterized by expression of a fusion protein which comprises a member of the E-twenty-six (ETS) family, the method comprising:
- (a) analyzing in a sample of the subject for the presence of a genomic ETS rearrangement;
- and
- (b) administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol upon identification of said genomic ETS rearrangement, thereby treating the cancer.
A method of treating a subject having a cancer characterized by expression of a fusion protein which comprises a member of the E-twenty-six (ETS) family, the method comprising:
- (a) analyzing in a sample of the subject for the presence of a genomic ETS rearrangement;
- and
- (b) administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol upon identification of said genomic ETS rearrangement, or administering to the subject a therapeutically effective amount of an anti-cancer agent other than an agent that inhibits the synthesis and/or activity of cortisol upon identification of an absence of said genomic ETS rearrangement, thereby treating the cancer.
Dependencies are inferred from the claim text.